Financial Futures Ltd Liability Co. bought a new stake in Pfizer Inc. (NYSE: PFE – Get a rating) during the 2nd quarter, according to the company’s most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,750 shares of the biopharmaceutical company’s stock, valued at approximately $249,000.
A number of other large investors have also recently bought and sold shares of PFE. Norges Bank acquired a new position in shares of Pfizer in the 4th quarter worth about $3,351,891,000. Capital International Investors boosted its position in Pfizer by 3,059.6% during the first quarter. Capital International Investors now owns 38,530,003 shares of the biopharmaceutical company’s stock worth $1,994,698,000 after purchasing an additional 37,310,556 shares in the last quarter. Vanguard Group Inc. boosted its stake in Pfizer by 3.0% in the first quarter. Now Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock valued at $24,801,210,000 after buying an additional 13,790,348 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Pfizer by 28.2% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 43,391,119 shares of the biopharmaceutical company’s stock valued at $2,246,359,000 after buying an additional 9,537,621 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its stake in shares of Pfizer by 1,080.2% during the first quarter. Los Angeles Capital Management LLC now owns 8,200,204 shares of the biopharmaceutical company’s stock valued at $424,525,000 after buying an additional 7,505,371 shares in the last quarter. Institutional investors and hedge funds own 67.90% of the company’s shares.
Pfizer stock performance
NYSE PFE opened at $43.76 on Friday. Pfizer Inc. has a 12-month low of $40.94 and a 12-month high of $61.71. The firm has a 50-day moving average of $47.54 and a 200-day moving average of $50.06. The company has a market cap of $245.60 billion, a P/E ratio of 8.56, a P/E/G ratio of 0.54 and a beta of 0.70. The company has a gearing ratio of 1.20, a current ratio of 1.42, and a debt-to-equity ratio of 0.39.
Pfizer (NYSE: PFE – Get a rating) last published its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.29. Pfizer’s return on equity was 43.18% and its net margin was 28.92%. The company had revenue of $27.74 billion for the quarter, compared to analysts’ expectations of $26.20 billion. For the same period last year, earnings per share amounted to $1.07. The company’s revenue for the quarter grew by 46.8% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 6.54 earnings per share for the current year.
Pfizer’s dividend announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be given a $0.40 dividend. This amounts to $1.60 in annualized dividends and a dividend yield of 3.66%. The ex-dividend date of this dividend is Thursday, November 3rd. Pfizer’s payout ratio is currently 31.31%.
Changes in analysts’ ratings
Several research firms have recently weighed in on PFE. Berenberg Bank set a $44.00 target price on shares of Pfizer in a research note on Wednesday, September 14th. SVB Leerink reduced their price objective on shares of Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a research note on Friday, July 29th. UBS Group restated a $59.00 target price on shares of Pfizer in a report on Thursday, September 1st. JPMorgan Chase & Co. set a $57.00 target price on Pfizer in a report on Tuesday, June 28th. Finally, Morgan Stanley cut their price objective on Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a research report on Friday, July 8th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $57.00, according to MarketBeat.
Pfizer Inc discovers, develops, manufactures, markets, distributes and markets biopharmaceutical products worldwide. It offers drugs and vaccines in a variety of therapeutic areas, including cardiovascular and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapy and biosimilars under the brands Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi; and sterile injectable and anti-infective drugs, as well as oral treatment for COVID-19 under the brand names Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.
Get Pfizer news and ratings daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies. MarketBeat.com’s FREE Daily E-Newsletter.
https://www.defenseworld.net/2022/10/02/4750-shares-in-pfizer-inc-nysepfe-purchased-by-financial-futures-ltd-liability-co.html 4,750 shares of Pfizer Inc. (NYSE:PFE), acquired by Financial Futures Ltd Liability Co.